| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 8.91e-12 | 14 | 29 | 5 | GO:0005130 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 1.48e-10 | 23 | 29 | 5 | GO:0034235 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 5.21e-10 | 29 | 29 | 5 | GO:0035325 | |
| GeneOntologyMolecularFunction | filamin binding | 5.21e-10 | 29 | 29 | 5 | GO:0031005 | |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 1.21e-09 | 34 | 29 | 5 | GO:0015125 | |
| GeneOntologyMolecularFunction | glycolipid binding | 8.19e-09 | 49 | 29 | 5 | GO:0051861 | |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 5.09e-08 | 70 | 29 | 5 | GO:1901618 | |
| GeneOntologyMolecularFunction | lipid transmembrane transporter activity | 6.30e-08 | 73 | 29 | 5 | GO:0170055 | |
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 1.81e-07 | 90 | 29 | 5 | GO:0008028 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 3.26e-07 | 196 | 29 | 6 | GO:0005319 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 2.22e-06 | 149 | 29 | 5 | GO:1990782 | |
| GeneOntologyMolecularFunction | growth factor receptor binding | 4.62e-06 | 173 | 29 | 5 | GO:0070851 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 1.11e-05 | 207 | 29 | 5 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 1.13e-05 | 208 | 29 | 5 | GO:0005342 | |
| GeneOntologyMolecularFunction | protein phosphatase binding | 1.19e-05 | 210 | 29 | 5 | GO:0019903 | |
| GeneOntologyMolecularFunction | calmodulin binding | 1.84e-05 | 230 | 29 | 5 | GO:0005516 | |
| GeneOntologyMolecularFunction | phosphatase binding | 3.56e-05 | 264 | 29 | 5 | GO:0019902 | |
| GeneOntologyMolecularFunction | actin binding | 5.49e-05 | 479 | 29 | 6 | GO:0003779 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 5.85e-05 | 293 | 29 | 5 | GO:0008514 | |
| GeneOntologyMolecularFunction | phosphatidylinositol binding | 8.36e-05 | 316 | 29 | 5 | GO:0035091 | |
| GeneOntologyMolecularFunction | cytokine receptor binding | 9.40e-05 | 324 | 29 | 5 | GO:0005126 | |
| GeneOntologyMolecularFunction | protein heterodimerization activity | 2.46e-04 | 398 | 29 | 5 | GO:0046982 | |
| GeneOntologyMolecularFunction | cytoskeletal protein binding | 8.04e-04 | 1099 | 29 | 7 | GO:0008092 | |
| GeneOntologyMolecularFunction | protein homodimerization activity | 9.63e-04 | 815 | 29 | 6 | GO:0042803 | |
| GeneOntologyMolecularFunction | phospholipid binding | 1.05e-03 | 548 | 29 | 5 | GO:0005543 | |
| GeneOntologyMolecularFunction | transporter activity | 2.04e-03 | 1289 | 29 | 7 | GO:0005215 | |
| GeneOntologyMolecularFunction | transmembrane transporter activity | 6.18e-03 | 1180 | 29 | 6 | GO:0022857 | |
| GeneOntologyMolecularFunction | protein dimerization activity | 6.83e-03 | 1205 | 29 | 6 | GO:0046983 | |
| GeneOntologyMolecularFunction | protein kinase binding | 7.83e-03 | 873 | 29 | 5 | GO:0019901 | |
| GeneOntologyMolecularFunction | kinase binding | 1.20e-02 | 969 | 29 | 5 | GO:0019900 | |
| GeneOntologyMolecularFunction | lipid binding | 1.30e-02 | 988 | 29 | 5 | GO:0008289 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 5.16e-12 | 14 | 27 | 5 | GO:0070348 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 7.73e-12 | 15 | 27 | 5 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 7.73e-12 | 15 | 27 | 5 | GO:0002859 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 7.73e-12 | 15 | 27 | 5 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 7.73e-12 | 15 | 27 | 5 | GO:1903387 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 1.12e-11 | 16 | 27 | 5 | GO:0038016 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 1.59e-11 | 17 | 27 | 5 | GO:0070342 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 1.59e-11 | 17 | 27 | 5 | GO:0038158 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 1.59e-11 | 17 | 27 | 5 | GO:1901143 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 2.20e-11 | 18 | 27 | 5 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 3.97e-11 | 20 | 27 | 5 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 5.21e-11 | 21 | 27 | 5 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 5.21e-11 | 21 | 27 | 5 | GO:0002838 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 5.21e-11 | 21 | 27 | 5 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 6.73e-11 | 22 | 27 | 5 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 8.60e-11 | 23 | 27 | 5 | GO:0090331 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 8.60e-11 | 23 | 27 | 5 | GO:0002858 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 1.09e-10 | 24 | 27 | 5 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 1.09e-10 | 24 | 27 | 5 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 1.09e-10 | 24 | 27 | 5 | GO:0002420 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 1.36e-10 | 25 | 27 | 5 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 1.36e-10 | 25 | 27 | 5 | GO:0002423 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 2.06e-10 | 27 | 27 | 5 | GO:0070344 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 2.50e-10 | 28 | 27 | 5 | GO:0034111 | |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 3.02e-10 | 29 | 27 | 5 | GO:2001212 | |
| GeneOntologyBiologicalProcess | negative regulation of coagulation | 4.09e-10 | 72 | 27 | 6 | GO:0050819 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 4.31e-10 | 31 | 27 | 5 | GO:0010544 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 5.10e-10 | 32 | 27 | 5 | GO:0060312 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 5.10e-10 | 32 | 27 | 5 | GO:0045779 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 5.10e-10 | 32 | 27 | 5 | GO:0070341 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 6.01e-10 | 33 | 27 | 5 | GO:2000252 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 6.01e-10 | 33 | 27 | 5 | GO:0030852 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 7.04e-10 | 34 | 27 | 5 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 7.04e-10 | 34 | 27 | 5 | GO:0046851 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 8.21e-10 | 35 | 27 | 5 | GO:1901142 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 1.27e-09 | 38 | 27 | 5 | GO:2000345 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 1.45e-09 | 39 | 27 | 5 | GO:0045717 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 1.66e-09 | 40 | 27 | 5 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 1.88e-09 | 41 | 27 | 5 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 2.14e-09 | 42 | 27 | 5 | GO:0090330 | |
| GeneOntologyBiologicalProcess | regulation of coagulation | 2.37e-09 | 96 | 27 | 6 | GO:0050818 | |
| GeneOntologyBiologicalProcess | negative regulation of wound healing | 2.69e-09 | 98 | 27 | 6 | GO:0061045 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 3.06e-09 | 45 | 27 | 5 | GO:0048521 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 3.43e-09 | 46 | 27 | 5 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 3.43e-09 | 46 | 27 | 5 | GO:0072574 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 3.84e-09 | 47 | 27 | 5 | GO:0015721 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 3.84e-09 | 47 | 27 | 5 | GO:0001911 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 3.84e-09 | 47 | 27 | 5 | GO:0034104 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 4.76e-09 | 49 | 27 | 5 | GO:0072576 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 4.76e-09 | 49 | 27 | 5 | GO:0002837 | |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 5.28e-09 | 50 | 27 | 5 | GO:0002834 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 6.47e-09 | 52 | 27 | 5 | GO:0031342 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 7.14e-09 | 53 | 27 | 5 | GO:0034110 | |
| GeneOntologyBiologicalProcess | vasculogenesis | 8.28e-09 | 118 | 27 | 6 | GO:0001570 | |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 9.48e-09 | 56 | 27 | 5 | GO:0002418 | |
| GeneOntologyBiologicalProcess | negative regulation of response to wounding | 1.23e-08 | 126 | 27 | 6 | GO:1903035 | |
| GeneOntologyBiologicalProcess | negative regulation of osteoclast differentiation | 1.24e-08 | 59 | 27 | 5 | GO:0045671 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 1.35e-08 | 60 | 27 | 5 | GO:0030851 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 1.35e-08 | 60 | 27 | 5 | GO:0045922 | |
| GeneOntologyBiologicalProcess | regulation of behavior | 1.35e-08 | 128 | 27 | 6 | GO:0050795 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 1.47e-08 | 61 | 27 | 5 | GO:0060259 | |
| GeneOntologyBiologicalProcess | regulation of platelet activation | 2.20e-08 | 66 | 27 | 5 | GO:0010543 | |
| GeneOntologyBiologicalProcess | regulation of endothelial cell differentiation | 2.37e-08 | 67 | 27 | 5 | GO:0045601 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 2.76e-08 | 69 | 27 | 5 | GO:0030195 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 2.97e-08 | 70 | 27 | 5 | GO:0045124 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 2.97e-08 | 70 | 27 | 5 | GO:1900047 | |
| GeneOntologyBiologicalProcess | regulation of vascular permeability | 3.19e-08 | 71 | 27 | 5 | GO:0043114 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 3.19e-08 | 71 | 27 | 5 | GO:0002347 | |
| GeneOntologyBiologicalProcess | negative regulation of interleukin-1 production | 3.42e-08 | 72 | 27 | 5 | GO:0032692 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid biosynthetic process | 3.67e-08 | 73 | 27 | 5 | GO:0042304 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 4.50e-08 | 76 | 27 | 5 | GO:0042269 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 5.84e-08 | 80 | 27 | 5 | GO:0046850 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 5.84e-08 | 80 | 27 | 5 | GO:0002715 | |
| GeneOntologyBiologicalProcess | regulation of wound healing | 6.39e-08 | 166 | 27 | 6 | GO:0061041 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 7.03e-08 | 83 | 27 | 5 | GO:0002707 | |
| GeneOntologyBiologicalProcess | regulation of sprouting angiogenesis | 7.93e-08 | 85 | 27 | 5 | GO:1903670 | |
| GeneOntologyBiologicalProcess | negative regulation of myeloid leukocyte differentiation | 7.93e-08 | 85 | 27 | 5 | GO:0002762 | |
| GeneOntologyBiologicalProcess | regulation of epidermal growth factor receptor signaling pathway | 8.41e-08 | 86 | 27 | 5 | GO:0042058 | |
| GeneOntologyBiologicalProcess | blood vessel remodeling | 8.92e-08 | 87 | 27 | 5 | GO:0001974 | |
| GeneOntologyBiologicalProcess | negative regulation of lipid biosynthetic process | 1.12e-07 | 91 | 27 | 5 | GO:0051055 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 1.12e-07 | 91 | 27 | 5 | GO:0030193 | |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 1.25e-07 | 93 | 27 | 5 | GO:1900046 | |
| GeneOntologyBiologicalProcess | regulation of ERBB signaling pathway | 1.25e-07 | 93 | 27 | 5 | GO:1901184 | |
| GeneOntologyBiologicalProcess | platelet aggregation | 1.39e-07 | 95 | 27 | 5 | GO:0070527 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 1.46e-07 | 96 | 27 | 5 | GO:0002704 | |
| GeneOntologyBiologicalProcess | bone resorption | 1.71e-07 | 99 | 27 | 5 | GO:0045453 | |
| GeneOntologyBiologicalProcess | regulation of cell growth | 2.22e-07 | 519 | 27 | 8 | GO:0001558 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 2.29e-07 | 105 | 27 | 5 | GO:0042267 | |
| GeneOntologyBiologicalProcess | negative regulation of T cell proliferation | 2.52e-07 | 107 | 27 | 5 | GO:0042130 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immunity | 2.76e-07 | 109 | 27 | 5 | GO:0002228 | |
| GeneOntologyBiologicalProcess | regulation of response to wounding | 3.11e-07 | 217 | 27 | 6 | GO:1903034 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 3.46e-07 | 114 | 27 | 5 | GO:0045824 | |
| GeneOntologyBiologicalProcess | regulation of osteoclast differentiation | 3.77e-07 | 116 | 27 | 5 | GO:0045670 | |
| GeneOntologyBiologicalProcess | negative regulation of epithelial cell proliferation | 3.95e-07 | 226 | 27 | 6 | GO:0050680 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte proliferation | 5.26e-07 | 124 | 27 | 5 | GO:0050672 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated cytotoxicity | 5.26e-07 | 124 | 27 | 5 | GO:0001910 | |
| GeneOntologyBiologicalProcess | homotypic cell-cell adhesion | 5.26e-07 | 124 | 27 | 5 | GO:0034109 | |
| GeneOntologyBiologicalProcess | negative regulation of mononuclear cell proliferation | 5.69e-07 | 126 | 27 | 5 | GO:0032945 | |
| GeneOntologyBiologicalProcess | bone remodeling | 5.92e-07 | 127 | 27 | 5 | GO:0046849 | |
| GeneOntologyBiologicalProcess | regulation of tissue remodeling | 6.16e-07 | 128 | 27 | 5 | GO:0034103 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 2.21e-11 | 16 | 31 | 5 | GO:0070021 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 2.06e-07 | 90 | 31 | 5 | GO:0016328 | |
| GeneOntologyCellularComponent | ciliary membrane | 3.15e-07 | 98 | 31 | 5 | GO:0060170 | |
| GeneOntologyCellularComponent | serine/threonine protein kinase complex | 3.25e-06 | 157 | 31 | 5 | GO:1902554 | |
| GeneOntologyCellularComponent | T cell receptor complex | 3.91e-06 | 163 | 31 | 5 | GO:0042101 | |
| GeneOntologyCellularComponent | protein kinase complex | 4.80e-06 | 170 | 31 | 5 | GO:1902911 | |
| GeneOntologyCellularComponent | adherens junction | 1.40e-05 | 212 | 31 | 5 | GO:0005912 | |
| GeneOntologyCellularComponent | basolateral plasma membrane | 9.98e-05 | 320 | 31 | 5 | GO:0016323 | |
| GeneOntologyCellularComponent | transferase complex, transferring phosphorus-containing groups | 1.24e-04 | 335 | 31 | 5 | GO:0061695 | |
| GeneOntologyCellularComponent | plasma membrane signaling receptor complex | 1.52e-04 | 350 | 31 | 5 | GO:0098802 | |
| GeneOntologyCellularComponent | basal plasma membrane | 1.60e-04 | 354 | 31 | 5 | GO:0009925 | |
| GeneOntologyCellularComponent | basal part of cell | 2.17e-04 | 378 | 31 | 5 | GO:0045178 | |
| GeneOntologyCellularComponent | cell projection membrane | 3.97e-04 | 431 | 31 | 5 | GO:0031253 | |
| GeneOntologyCellularComponent | apical plasma membrane | 6.92e-04 | 487 | 31 | 5 | GO:0016324 | |
| GeneOntologyCellularComponent | plasma membrane protein complex | 9.06e-04 | 785 | 31 | 6 | GO:0098797 | |
| GeneOntologyCellularComponent | external side of plasma membrane | 9.22e-04 | 519 | 31 | 5 | GO:0009897 | |
| GeneOntologyCellularComponent | receptor complex | 1.52e-03 | 581 | 31 | 5 | GO:0043235 | |
| GeneOntologyCellularComponent | cell-cell junction | 1.64e-03 | 591 | 31 | 5 | GO:0005911 | |
| GeneOntologyCellularComponent | apical part of cell | 1.65e-03 | 592 | 31 | 5 | GO:0045177 | |
| GeneOntologyCellularComponent | cilium | 1.81e-03 | 898 | 31 | 6 | GO:0005929 | |
| GeneOntologyCellularComponent | transferase complex | 2.58e-03 | 963 | 31 | 6 | GO:1990234 | |
| GeneOntologyCellularComponent | membrane protein complex | 5.47e-03 | 1498 | 31 | 7 | GO:0098796 | |
| GeneOntologyCellularComponent | side of membrane | 8.73e-03 | 875 | 31 | 5 | GO:0098552 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 2.14e-11 | 17 | 20 | 5 | MP:0031047 | |
| MousePheno | increased skeletal muscle triglyceride level | 7.00e-11 | 21 | 20 | 5 | MP:0031415 | |
| MousePheno | decreased fatty acid oxidation | 1.46e-10 | 24 | 20 | 5 | MP:0014172 | |
| MousePheno | increased abdominal fat pad weight | 2.76e-10 | 27 | 20 | 5 | MP:0009286 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 3.36e-10 | 28 | 20 | 5 | MP:0020950 | |
| MousePheno | decreased carbon dioxide production | 5.79e-10 | 31 | 20 | 5 | MP:0008964 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 5.79e-10 | 31 | 20 | 5 | MP:0031413 | |
| MousePheno | decreased skeletal muscle cell glucose uptake | 1.10e-09 | 35 | 20 | 5 | MP:0031618 | |
| MousePheno | decreased susceptibility to Riboviria infection | 1.23e-09 | 82 | 20 | 6 | MP:0020914 | |
| MousePheno | abnormal muscle triglyceride level | 1.28e-09 | 36 | 20 | 5 | MP:0031412 | |
| MousePheno | decreased muscle cell glucose uptake | 1.95e-09 | 39 | 20 | 5 | MP:0030022 | |
| MousePheno | decreased susceptibility to Riboviria infection induced morbidity/mortality | 3.66e-09 | 44 | 20 | 5 | MP:0031023 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 5.15e-09 | 47 | 20 | 5 | MP:0031617 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 6.39e-09 | 49 | 20 | 5 | MP:0020948 | |
| MousePheno | obese | 8.63e-09 | 113 | 20 | 6 | MP:0001261 | |
| MousePheno | decreased cellular glucose uptake | 9.59e-09 | 53 | 20 | 5 | MP:0003926 | |
| MousePheno | abnormal fatty acid oxidation | 1.06e-08 | 54 | 20 | 5 | MP:0010953 | |
| MousePheno | decreased susceptibility to viral infection | 1.59e-08 | 125 | 20 | 6 | MP:0002410 | |
| MousePheno | decreased susceptibility to viral infection induced morbidity/mortality | 1.81e-08 | 60 | 20 | 5 | MP:0009790 | |
| MousePheno | abnormal lipid oxidation | 1.97e-08 | 61 | 20 | 5 | MP:0010951 | |
| MousePheno | increased insulin secretion | 2.52e-08 | 64 | 20 | 5 | MP:0003058 | |
| MousePheno | abnormal muscle cell glucose uptake | 3.19e-08 | 67 | 20 | 5 | MP:0004130 | |
| MousePheno | abnormal carbon dioxide production | 3.19e-08 | 67 | 20 | 5 | MP:0008962 | |
| MousePheno | abnormal vascular wound healing | 4.93e-08 | 73 | 20 | 5 | MP:0004883 | |
| MousePheno | abnormal colon morphology | 5.12e-08 | 152 | 20 | 6 | MP:0000495 | |
| MousePheno | decreased oxygen consumption | 7.36e-08 | 79 | 20 | 5 | MP:0005290 | |
| MousePheno | polyphagia | 7.84e-08 | 80 | 20 | 5 | MP:0001433 | |
| MousePheno | abnormal susceptibility to Riboviria infection | 1.70e-07 | 186 | 20 | 6 | MP:0020912 | |
| MousePheno | abnormal wound healing | 2.11e-07 | 193 | 20 | 6 | MP:0005023 | |
| MousePheno | abnormal cellular glucose uptake | 2.66e-07 | 102 | 20 | 5 | MP:0003925 | |
| MousePheno | decreased respiratory quotient | 3.89e-07 | 110 | 20 | 5 | MP:0010379 | |
| MousePheno | decreased energy expenditure | 5.75e-07 | 119 | 20 | 5 | MP:0004890 | |
| MousePheno | decreased susceptibility to infection induced morbidity/mortality | 6.00e-07 | 120 | 20 | 5 | MP:0009786 | |
| MousePheno | increased circulating leptin level | 7.35e-07 | 125 | 20 | 5 | MP:0005669 | |
| MousePheno | decreased susceptibility to infection | 1.09e-06 | 255 | 20 | 6 | MP:0002409 | |
| MousePheno | increased incidence of tumors by chemical induction | 1.33e-06 | 141 | 20 | 5 | MP:0004499 | |
| MousePheno | abnormal glycogen homeostasis | 1.48e-06 | 144 | 20 | 5 | MP:0005438 | |
| MousePheno | abnormal large intestine morphology | 1.72e-06 | 276 | 20 | 6 | MP:0000489 | |
| MousePheno | abnormal susceptibility to viral infection | 1.83e-06 | 279 | 20 | 6 | MP:0020185 | |
| MousePheno | abnormal insulin secretion | 3.45e-06 | 171 | 20 | 5 | MP:0003564 | |
| MousePheno | increased incidence of induced tumors | 3.65e-06 | 173 | 20 | 5 | MP:0002021 | |
| MousePheno | abnormal endocrine pancreas secretion | 3.98e-06 | 176 | 20 | 5 | MP:0014195 | |
| MousePheno | abnormal respiratory quotient | 4.20e-06 | 178 | 20 | 5 | MP:0004129 | |
| MousePheno | abnormal pancreas secretion | 4.81e-06 | 183 | 20 | 5 | MP:0002694 | |
| MousePheno | increased food intake | 5.63e-06 | 189 | 20 | 5 | MP:0011939 | |
| MousePheno | abnormal oxygen consumption | 6.56e-06 | 195 | 20 | 5 | MP:0005288 | |
| MousePheno | abnormal intestine morphology | 6.64e-06 | 546 | 20 | 7 | MP:0000477 | |
| MousePheno | abnormal pancreatic beta cell physiology | 6.73e-06 | 196 | 20 | 5 | MP:0003562 | |
| MousePheno | insulin resistance | 6.90e-06 | 197 | 20 | 5 | MP:0005331 | |
| MousePheno | increased triglyceride level | 7.26e-06 | 354 | 20 | 6 | MP:0005317 | |
| MousePheno | abnormal endocrine pancreas physiology | 7.79e-06 | 202 | 20 | 5 | MP:0010147 | |
| MousePheno | increased total tissue mass | 8.51e-06 | 364 | 20 | 6 | MP:0012323 | |
| MousePheno | increased body weight | 8.51e-06 | 364 | 20 | 6 | MP:0001260 | |
| MousePheno | abnormal blood vessel physiology | 1.34e-05 | 394 | 20 | 6 | MP:0000249 | |
| MousePheno | abnormal vasculature physiology | 1.54e-05 | 404 | 20 | 6 | MP:0031170 | |
| MousePheno | increased body size | 1.65e-05 | 409 | 20 | 6 | MP:0001264 | |
| MousePheno | abnormal circulating leptin level | 1.66e-05 | 236 | 20 | 5 | MP:0005667 | |
| MousePheno | abnormal abdominal fat pad morphology | 2.74e-05 | 262 | 20 | 5 | MP:0000010 | |
| MousePheno | abnormal incidence of induced tumors | 3.11e-05 | 269 | 20 | 5 | MP:0013151 | |
| MousePheno | decreased circulating triglyceride level | 3.46e-05 | 275 | 20 | 5 | MP:0002644 | |
| MousePheno | abnormal susceptibility to infection induced morbidity/mortality | 3.70e-05 | 279 | 20 | 5 | MP:0009785 | |
| MousePheno | increased circulating insulin level | 3.97e-05 | 283 | 20 | 5 | MP:0002079 | |
| MousePheno | increased physiological sensitivity to xenobiotic | 4.17e-05 | 286 | 20 | 5 | MP:0008873 | |
| MousePheno | abnormal pancreas physiology | 4.61e-05 | 292 | 20 | 5 | MP:0002693 | |
| MousePheno | abnormal circulating triglyceride level | 6.12e-05 | 516 | 20 | 6 | MP:0011969 | |
| MousePheno | abnormal energy expenditure | 6.41e-05 | 313 | 20 | 5 | MP:0005450 | |
| MousePheno | abnormal fat pad morphology | 6.51e-05 | 314 | 20 | 5 | MP:0005334 | |
| MousePheno | increased tumor incidence | 7.10e-05 | 530 | 20 | 6 | MP:0002020 | |
| MousePheno | abnormal energy homeostasis | 7.33e-05 | 322 | 20 | 5 | MP:0005448 | |
| MousePheno | decreased triglyceride level | 1.06e-04 | 348 | 20 | 5 | MP:0005318 | |
| MousePheno | increased lipid level | 1.13e-04 | 847 | 20 | 7 | MP:0014460 | |
| MousePheno | increased lean body mass | 1.15e-04 | 354 | 20 | 5 | MP:0003960 | |
| MousePheno | abnormal endocrine gland physiology | 1.29e-04 | 363 | 20 | 5 | MP:0013561 | |
| MousePheno | abnormal response to injury | 1.50e-04 | 607 | 20 | 6 | MP:0005164 | |
| MousePheno | abnormal tumor incidence | 1.92e-04 | 635 | 20 | 6 | MP:0002019 | |
| MousePheno | abnormal triglyceride level | 1.99e-04 | 639 | 20 | 6 | MP:0000187 | |
| MousePheno | abnormal tumor susceptibility | 2.19e-04 | 650 | 20 | 6 | MP:0002166 | |
| MousePheno | abnormal susceptibility to infection | 2.62e-04 | 672 | 20 | 6 | MP:0001793 | |
| MousePheno | increased total body fat amount | 2.67e-04 | 424 | 20 | 5 | MP:0010024 | |
| MousePheno | abnormal gland physiology | 3.05e-04 | 691 | 20 | 6 | MP:0002164 | |
| MousePheno | abnormal response to infection | 3.64e-04 | 714 | 20 | 6 | MP:0005025 | |
| MousePheno | abnormal response to antigen | 3.98e-04 | 726 | 20 | 6 | MP:0020000 | |
| MousePheno | abnormal induced morbidity/mortality | 4.31e-04 | 737 | 20 | 6 | MP:0001657 | |
| MousePheno | neoplasm | 4.64e-04 | 747 | 20 | 6 | MP:0002006 | |
| MousePheno | impaired glucose tolerance | 4.72e-04 | 480 | 20 | 5 | MP:0005293 | |
| MousePheno | abnormal food intake | 4.77e-04 | 481 | 20 | 5 | MP:0005449 | |
| MousePheno | abnormal circulating insulin level | 5.96e-04 | 505 | 20 | 5 | MP:0001560 | |
| MousePheno | abnormal skeletal muscle morphology | 6.12e-04 | 508 | 20 | 5 | MP:0000759 | |
| MousePheno | increased circulating hormone level | 1.10e-03 | 578 | 20 | 5 | MP:0014456 | |
| MousePheno | abnormal digestive system morphology | 1.13e-03 | 1233 | 20 | 7 | MP:0000462 | |
| MousePheno | abnormal gas homeostasis | 1.30e-03 | 600 | 20 | 5 | MP:0003948 | |
| MousePheno | abnormal eating behavior | 1.34e-03 | 604 | 20 | 5 | MP:0001431 | |
| MousePheno | abnormal circulating lipid level | 1.58e-03 | 1305 | 20 | 7 | MP:0003949 | |
| MousePheno | increased hormone level | 1.74e-03 | 641 | 20 | 5 | MP:0014454 | |
| MousePheno | abnormal physiological response to xenobiotic | 2.01e-03 | 662 | 20 | 5 | MP:0008872 | |
| MousePheno | abnormal consumption behavior | 2.49e-03 | 695 | 20 | 5 | MP:0002069 | |
| Domain | Ig_2 | 1.25e-07 | 73 | 31 | 5 | PF13895 | |
| Domain | V-set | 1.21e-05 | 184 | 31 | 5 | PF07686 | |
| Domain | ig | 1.42e-05 | 190 | 31 | 5 | PF00047 | |
| Domain | Immunoglobulin | 1.42e-05 | 190 | 31 | 5 | IPR013151 | |
| Domain | Ig_V-set | 1.77e-05 | 199 | 31 | 5 | IPR013106 | |
| Domain | IGc2 | 3.93e-05 | 235 | 31 | 5 | SM00408 | |
| Domain | Ig_sub2 | 3.93e-05 | 235 | 31 | 5 | IPR003598 | |
| Domain | IG | 5.95e-04 | 421 | 31 | 5 | SM00409 | |
| Domain | Ig_sub | 5.95e-04 | 421 | 31 | 5 | IPR003599 | |
| Domain | IG_LIKE | 1.19e-03 | 491 | 31 | 5 | PS50835 | |
| Domain | Ig-like_dom | 1.32e-03 | 503 | 31 | 5 | IPR007110 | |
| Domain | - | 4.39e-03 | 663 | 31 | 5 | 2.60.40.10 | |
| Domain | Ig-like_fold | 5.72e-03 | 706 | 31 | 5 | IPR013783 | |
| Pathway | REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS | 4.70e-07 | 99 | 23 | 5 | MM14624 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 4.75e-06 | 158 | 23 | 5 | MM14812 | |
| Pathway | WP_EGFR1_SIGNALING_PATHWAY | 1.11e-05 | 188 | 23 | 5 | MM15828 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 1.29e-05 | 194 | 23 | 5 | M16312 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 5.07e-05 | 258 | 23 | 5 | MM14572 | |
| Pathway | REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION | 1.94e-04 | 1389 | 23 | 9 | MM15307 | |
| Pathway | REACTOME_NEUTROPHIL_DEGRANULATION | 1.20e-03 | 511 | 23 | 5 | MM15330 | |
| Pathway | REACTOME_HEMOSTASIS | 1.96e-03 | 571 | 23 | 5 | MM14472 | |
| Pathway | REACTOME_HEMOSTASIS | 4.17e-03 | 679 | 23 | 5 | M8395 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 5.13e-13 | 13 | 31 | 5 | 12832451 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 26219866 | ||
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 5.13e-13 | 13 | 31 | 5 | 34058224 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 25406283 | ||
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 5.13e-13 | 13 | 31 | 5 | 1985902 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 15207636 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 7628460 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 19285068 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 25724769 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 18003729 | ||
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 5.13e-13 | 13 | 31 | 5 | 15316023 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 21760897 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 26284027 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 2133556 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 8402684 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 20404914 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 32521208 | ||
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 5.13e-13 | 13 | 31 | 5 | 22092845 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 16680193 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 26374765 | ||
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 5.13e-13 | 13 | 31 | 5 | 21670291 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 22162753 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 11801635 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 1719235 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 2164599 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 26911181 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 5.13e-13 | 13 | 31 | 5 | 33352461 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 1653760 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 19406938 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 10964771 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 38381498 | ||
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 5.13e-13 | 13 | 31 | 5 | 23935487 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 2702644 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 28913658 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 32169849 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 16619040 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 5.13e-13 | 13 | 31 | 5 | 32027621 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 20739537 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 19008452 | ||
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 5.13e-13 | 13 | 31 | 5 | 19273835 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 19621080 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 5.13e-13 | 13 | 31 | 5 | 25972571 | |
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 5.13e-13 | 13 | 31 | 5 | 29967450 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 5.13e-13 | 13 | 31 | 5 | 16638824 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 8380065 | ||
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 5.13e-13 | 13 | 31 | 5 | 1326665 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 18544705 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 1279194 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 20044046 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 1633107 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 32150576 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 21081647 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 30664851 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 11133662 | ||
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 5.13e-13 | 13 | 31 | 5 | 39168268 | |
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 5.13e-13 | 13 | 31 | 5 | 27777319 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 22469976 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 15331748 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 29377208 | ||
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 5.13e-13 | 13 | 31 | 5 | 15220458 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 11483763 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 5.13e-13 | 13 | 31 | 5 | 8209741 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 5.13e-13 | 13 | 31 | 5 | 22406619 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 18848945 | ||
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 5.13e-13 | 13 | 31 | 5 | 19358828 | |
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 5.13e-13 | 13 | 31 | 5 | 8500759 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 5.13e-13 | 13 | 31 | 5 | 21949477 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 6265583 | ||
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 18843289 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 5.13e-13 | 13 | 31 | 5 | 21532628 | |
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 5.13e-13 | 13 | 31 | 5 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 5.13e-13 | 13 | 31 | 5 | 23800882 | |
| Pubmed | 5.13e-13 | 13 | 31 | 5 | 29396368 | ||
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 5.13e-13 | 13 | 31 | 5 | 27695943 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 5.13e-13 | 13 | 31 | 5 | 28035001 | |
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 37531413 | ||
| Pubmed | CEACAM1, a SOX9 direct transcriptional target identified in the colon epithelium. | 7.98e-13 | 14 | 31 | 5 | 18794798 | |
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 34619794 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 29907459 | ||
| Pubmed | Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. | 7.98e-13 | 14 | 31 | 5 | 32209360 | |
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 23780386 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 28567513 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 22962327 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 31083261 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 17623671 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 11994468 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 8207827 | ||
| Pubmed | Loss of CEACAM1 in endothelial cells causes hepatic fibrosis. | 7.98e-13 | 14 | 31 | 5 | 37088122 | |
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 26846848 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 11850617 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 14517298 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 23469261 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 18454175 | ||
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 1648219 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 7.98e-13 | 14 | 31 | 5 | 26196244 | |
| Pubmed | 7.98e-13 | 14 | 31 | 5 | 36719377 | ||
| Pubmed | CEACAM2 positively regulates integrin αIIbβ3-mediated platelet functions. | 7.98e-13 | 14 | 31 | 5 | 27161904 | |
| Interaction | PSG4 interactions | 1.49e-07 | 8 | 29 | 3 | int:PSG4 | |
| Interaction | PSG1 interactions | 8.24e-07 | 51 | 29 | 4 | int:PSG1 | |
| Interaction | NLGN3 interactions | 1.18e-05 | 99 | 29 | 4 | int:NLGN3 | |
| Interaction | PSG6 interactions | 1.20e-05 | 4 | 29 | 2 | int:PSG6 | |
| Interaction | PSG5 interactions | 1.99e-05 | 5 | 29 | 2 | int:PSG5 | |
| Interaction | CEACAM7 interactions | 4.18e-05 | 7 | 29 | 2 | int:CEACAM7 | |
| Interaction | ACTR5 interactions | 1.49e-04 | 72 | 29 | 3 | int:ACTR5 | |
| Interaction | PSG3 interactions | 4.54e-04 | 22 | 29 | 2 | int:PSG3 | |
| Interaction | PSG9 interactions | 4.54e-04 | 22 | 29 | 2 | int:PSG9 | |
| Cytoband | 19q13.2 | 8.62e-08 | 164 | 31 | 5 | 19q13.2 | |
| Cytoband | 12p13.33 | 7.49e-05 | 19 | 31 | 2 | 12p13.33 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr15q15 | 1.35e-04 | 147 | 31 | 3 | chr15q15 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr19q13 | 1.13e-03 | 1192 | 31 | 5 | chr19q13 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 4.43e-13 | 11 | 20 | 5 | 1315 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 7.78e-07 | 163 | 20 | 5 | 590 | |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 3.25e-10 | 32 | 31 | 5 | MM2 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 5.22e-10 | 35 | 31 | 5 | MM757 | |
| Coexpression | WANG_RESPONSE_TO_BEXAROTENE_UP | 2.72e-09 | 48 | 31 | 5 | MM531 | |
| Coexpression | HOLLERN_EMT_BREAST_TUMOR_DN | 1.11e-08 | 135 | 31 | 6 | MM965 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_5_6WK_UP | 1.56e-08 | 143 | 31 | 6 | MM989 | |
| Coexpression | BYSTROEM_CORRELATED_WITH_IL5_DN | 2.69e-08 | 75 | 31 | 5 | MM605 | |
| Coexpression | BOYLAN_MULTIPLE_MYELOMA_PCA3_DN | 5.69e-08 | 87 | 31 | 5 | MM851 | |
| Coexpression | MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP | 6.58e-08 | 182 | 31 | 6 | MM993 | |
| Coexpression | DESCARTES_FETAL_PLACENTA_TROPHOBLAST_GIANT_CELLS | 7.97e-08 | 93 | 31 | 5 | M40279 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_3_4WK_UP | 2.62e-07 | 230 | 31 | 6 | MM986 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP | 3.94e-07 | 128 | 31 | 5 | MM1000 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_DN | 1.15e-06 | 159 | 31 | 5 | MM760 | |
| Coexpression | OHGUCHI_LIVER_HNF4A_TARGETS_DN | 3.65e-06 | 201 | 31 | 5 | MM1294 | |
| Coexpression | BROWN_MYELOID_CELL_DEVELOPMENT_UP | 3.65e-06 | 201 | 31 | 5 | MM1006 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_MYELOID_CELL_AGEING | 5.54e-06 | 219 | 31 | 5 | MM3826 | |
| Coexpression | DESCARTES_FETAL_ADRENAL_CSH1_CSH2_POSITIVE_CELLS | 6.18e-06 | 224 | 31 | 5 | M40145 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_4_5WK_UP | 1.94e-05 | 284 | 31 | 5 | MM987 | |
| Coexpression | ZHANG_UTERUS_C1_REGENERATIVE_UP | 2.61e-05 | 302 | 31 | 5 | MM16604 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_EPITHELIAL_CELL_AGEING | 4.68e-05 | 568 | 31 | 6 | MM3824 | |
| Coexpression | FURUKAWA_DUSP6_TARGETS_PCI35_UP | 8.81e-05 | 73 | 31 | 3 | M6998 | |
| Coexpression | LIM_MAMMARY_STEM_CELL_DN | 1.48e-04 | 436 | 31 | 5 | MM1326 | |
| Coexpression | KUMAR_TARGETS_OF_MLL_AF9_FUSION | 1.96e-04 | 463 | 31 | 5 | MM1011 | |
| Coexpression | TABULA_MURIS_SENIS_GONADAL_ADIPOSE_TISSUE_ENDOTHELIAL_CELL_AGEING | 2.28e-04 | 1088 | 31 | 7 | MM3699 | |
| Coexpression | KOBAYASHI_EGFR_SIGNALING_24HR_UP | 2.38e-04 | 102 | 31 | 3 | M10290 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP | 2.54e-04 | 490 | 31 | 5 | MM1001 | |
| Coexpression | SWEET_LUNG_CANCER_KRAS_UP | 3.78e-04 | 534 | 31 | 5 | MM1050 | |
| Coexpression | BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS | 4.78e-04 | 871 | 31 | 6 | MM1005 | |
| CoexpressionAtlas | placenta | 6.52e-06 | 349 | 29 | 6 | placenta | |
| ToppCell | TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Keratinizing_Cervical_Squamous_Cell_Carcinoma-6|TCGA-Cervix / Sample_Type by Project: Shred V9 | 2.36e-06 | 136 | 31 | 4 | 2c723777fadc5946df67d3e992471d8134b827f4 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW19|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type. | 9.05e-06 | 191 | 31 | 4 | b5328733da3d3d77c4f6fc5e2ba2035f8898f172 | |
| ToppCell | Entopeduncular-Macroglia-POLYDENDROCYTE-P2-Tnr|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 3.34e-05 | 90 | 31 | 3 | 6adc78899a08d48da8ed4618ecf866c9ed9be059 | |
| ToppCell | Entopeduncular-Macroglia-POLYDENDROCYTE-P2-Tnr-Polydendrocyte.Tnr.Bmp4_(Bmp4)|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 3.34e-05 | 90 | 31 | 3 | a74f8172780adc1410e36e2718412010ee0ebf1f | |
| ToppCell | Entopeduncular-Macroglia-POLYDENDROCYTE-P2-Tnr-Polydendrocyte.Tnr.Bmp4_(Bmp4)-|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 3.34e-05 | 90 | 31 | 3 | 909ad62d175b657d8e541b0981ce8fed0ba7ed6c | |
| ToppCell | Entopeduncular-Macroglia-POLYDENDROCYTE-P2|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 3.34e-05 | 90 | 31 | 3 | 936c5078677ec934f3049d8aa5a14d930aa2e6dc | |
| ToppCell | Frontal_cortex-Macroglia-POLYDENDROCYTE-P2-Tnr|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 4.58e-05 | 100 | 31 | 3 | 187e31d4186b82a37569b98d83e4813017cc2ddd | |
| ToppCell | Frontal_cortex-Macroglia-POLYDENDROCYTE-P2|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 4.58e-05 | 100 | 31 | 3 | 3a7e5469de88745ac455c35deeb859d68dce73fa | |
| Computational | Neighborhood of EGFR | 3.15e-08 | 32 | 12 | 4 | GNF2_EGFR | |
| Computational | Neighborhood of IGFBP1 | 4.58e-08 | 35 | 12 | 4 | GNF2_IGFBP1 | |
| Computational | Neighborhood of MMP11 | 9.74e-08 | 42 | 12 | 4 | GNF2_MMP11 | |
| Computational | Neighborhood of TIMP2 | 1.42e-07 | 46 | 12 | 4 | GNF2_TIMP2 | |
| Computational | Neighborhood of KISS1 | 1.84e-07 | 49 | 12 | 4 | GNF2_KISS1 | |
| Computational | Neighborhood of CDKN1C | 3.06e-06 | 27 | 12 | 3 | GNF2_CDKN1C | |
| Computational | Neighborhood of FSHR | 3.20e-03 | 279 | 12 | 3 | MORF_FSHR | |
| Computational | Neighborhood of MLLT10 | 4.00e-03 | 302 | 12 | 3 | MORF_MLLT10 | |
| Computational | Neighborhood of SUPT3H | 5.05e-03 | 328 | 12 | 3 | MORF_SUPT3H | |
| Computational | Neighborhood of ATF2 | 5.13e-03 | 330 | 12 | 3 | MORF_ATF2 | |
| Drug | AC1L1IPV | 3.10e-09 | 43 | 31 | 5 | CID000004683 | |
| Drug | pP-8 | 2.72e-07 | 10 | 31 | 3 | CID000444681 | |
| Drug | Rgd Peptide | 7.43e-07 | 239 | 31 | 6 | CID000104802 | |
| Drug | Didemnins | 8.23e-07 | 14 | 31 | 3 | CID000123844 | |
| Drug | cyanogen-bromide | 1.33e-05 | 34 | 31 | 3 | CID000010476 | |
| Drug | AC1NUV1F | 2.53e-05 | 42 | 31 | 3 | CID005494395 | |
| Drug | NSC-4928 | 6.70e-05 | 58 | 31 | 3 | CID000221086 | |
| Drug | Nebeldose | 7.42e-05 | 60 | 31 | 3 | CID000165707 | |
| Drug | Sp 1 (pharmaceutical) | 8.34e-05 | 548 | 31 | 6 | CID000099040 | |
| Drug | NSC709922 | 1.17e-04 | 12 | 31 | 2 | CID000399246 | |
| Drug | LY294002; Down 200; 10uM; PC3; HG-U133A | 1.42e-04 | 197 | 31 | 4 | 429_DN | |
| Drug | 7-hydroxycoumarin | 1.44e-04 | 75 | 31 | 3 | CID005281426 | |
| Drug | 16-epiestriol | 1.56e-04 | 77 | 31 | 3 | CID000003269 | |
| Disease | cD177 antigen measurement | 6.18e-07 | 18 | 28 | 3 | EFO_0021866 | |
| Disease | iritis | 1.17e-04 | 17 | 28 | 2 | EFO_1000997 | |
| Disease | pack-years measurement, systolic blood pressure | 4.78e-04 | 34 | 28 | 2 | EFO_0006335, EFO_0006526 | |
| Disease | hypospadias | 6.30e-04 | 39 | 28 | 2 | EFO_0004209 | |
| Disease | ascending aortic diameter | 7.79e-03 | 140 | 28 | 2 | EFO_0021787 | |
| Disease | hemorrhoid | 8.56e-03 | 147 | 28 | 2 | EFO_0009552 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| IKSWALGAIALLFLL | 1046 | O94910 | |
| WNKAGLLLFSELQLI | 401 | Q9C0A0 | |
| NKLLLLAVLGWLFQI | 741 | Q8IWY9 | |
| LGFQKTLLLWQARLK | 376 | Q8TCP9 | |
| LQGLLARWLALFLSL | 906 | Q9ULG1 | |
| LWLLLLGSSLNARFL | 31 | Q4G1C9 | |
| QAWLRQKLLVLGSLA | 6 | Q8IZT8 | |
| SNNGLVTLLWFLLLL | 201 | Q8NGJ1 | |
| LLLIAWGLQRLKSLN | 161 | Q8N1E6 | |
| HLFQNLLLFLWALLN | 21 | Q6ZMM2 | |
| SQKLSLLLLVFGLIW | 11 | Q96EE4 | |
| LKLFRNILLWNGLLT | 651 | P16383 | |
| FVQKTSALLWLLLLG | 46 | Q7Z3S7 | |
| GKIWNILLFLLTVQL | 401 | Q92819 | |
| TLWQFLLQLLLDQKH | 6 | P41970 | |
| QLKWADFSGLQQLLL | 2091 | Q5TBA9 | |
| KGLLLTALLLNFWNL | 16 | Q9UQ72 | |
| KGLLLTASLLNFWNL | 16 | P11464 | |
| KGLLLTALLLNFWNL | 16 | Q16557 | |
| TNLLLAWLLVLNLKG | 1126 | P56715 | |
| KGLLLTASLLNFWNL | 16 | Q00889 | |
| LWLQKLFLPNLTLFL | 291 | Q9NSC7 | |
| WLQSFLLLLFRSLKQ | 176 | O75192 | |
| LLLKINLFNHWVSGL | 36 | Q6UE05 | |
| LLLLLLHAGSAKNIW | 21 | Q9HC57 | |
| QLWFVRLALLVKLGL | 426 | Q8WVT3 | |
| LTFLLVGLLNHQWLK | 56 | Q8TAQ9 | |
| HNSFWLLKLLFLLGL | 151 | A6NH21 | |
| GSLWLLKLLRDIQLA | 6 | Q13470 | |
| KGLLLTASLLNFWNL | 16 | Q15238 | |
| LNVKIALFLLLFLWL | 226 | Q5GH70 |